rg7388 and Leukemia--Lymphocytic--Chronic--B-Cell

Several molecular subtypes of cancer are highly dependent on splicing for cell survival. There is a general interest in the therapeutic targeting of splicing by small molecules. E7107, a first-in-class spliceosome inhibitor, showed strong growth inhibitory activities against a large variety of human cancer xenografts. Chronic lymphocytic leukaemia (CLL) is a clinically heterogeneous hematologic malignancy, with approximately 90% of cases being

Topics: Antineoplastic Agents; Apoptosis; B-Lymphocytes; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Protein Isoforms; Proto-Oncogene Proteins c-mdm2; Pyrrolidines; Tumor Suppressor Protein p53

Chronic lymphocytic leukemia (CLL) is a genetically and clinically heterogeneous malignancy affecting older individuals. There are a number of current treatment options for CLL, including monoclonal antibodies, targeted drugs, chemotherapy, and different combinations of these. However, for those patients who are intrinsically treatment resistant, or relapse following initial responses, novel targeted therapies are still needed. Targeting the mouse double-minute-2 human homolog (MDM2), a primary negative regulator of p53, is an appealing therapeutic strategy for non-genotoxic reactivation of p53, since the

Topics: Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Phosphoproteins; Proto-Oncogene Proteins c-mdm2; RNA Splicing Factors; Tumor Suppressor Protein p53